X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (26228) 26228
Book Chapter (92) 92
Publication (24) 24
Dissertation (17) 17
Book / eBook (9) 9
Conference Proceeding (3) 3
Data Set (3) 3
Government Document (3) 3
Magazine Article (3) 3
Book Review (2) 2
Paper (1) 1
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (17909) 17909
humans (16303) 16303
oncology (8447) 8447
cancer (8056) 8056
animals (7431) 7431
apoptosis (7029) 7029
cell line, tumor (6480) 6480
cell biology (5727) 5727
cell cycle (5709) 5709
immunotherapy (5290) 5290
female (4330) 4330
mice (4123) 4123
biochemistry & molecular biology (4111) 4111
apoptosis - drug effects (3942) 3942
proteins (3805) 3805
phosphorylation (3761) 3761
tumors (3641) 3641
immune checkpoint (3605) 3605
expression (3554) 3554
dna damage (3357) 3357
cell cycle checkpoints - drug effects (3350) 3350
cell proliferation - drug effects (3186) 3186
male (2957) 2957
chemotherapy (2861) 2861
research (2813) 2813
kinases (2629) 2629
antineoplastic agents - pharmacology (2566) 2566
activation (2503) 2503
checkpoint (2456) 2456
signal transduction (2432) 2432
gene expression (2411) 2411
melanoma (2329) 2329
cell proliferation (2318) 2318
cell cycle proteins - metabolism (2294) 2294
analysis (2254) 2254
metastasis (2252) 2252
cancer therapies (2204) 2204
mutation (2183) 2183
care and treatment (2047) 2047
immunology (1974) 1974
nivolumab (1935) 1935
mitosis (1927) 1927
lymphocytes (1817) 1817
genetic aspects (1813) 1813
multidisciplinary sciences (1762) 1762
cytotoxicity (1742) 1742
protein-serine-threonine kinases - metabolism (1741) 1741
patients (1709) 1709
p53 (1707) 1707
deoxyribonucleic acid--dna (1677) 1677
lung cancer (1670) 1670
biology (1669) 1669
health aspects (1669) 1669
inhibition (1630) 1630
immune checkpoint inhibitors (1582) 1582
dna repair (1575) 1575
signal transduction - drug effects (1563) 1563
cell death (1562) 1562
therapy (1555) 1555
pharmacology & pharmacy (1543) 1543
research article (1524) 1524
cells (1521) 1521
tumor suppressor protein p53 - metabolism (1499) 1499
middle aged (1493) 1493
lymphocytes t (1487) 1487
genetics & heredity (1473) 1473
cell cycle checkpoints (1465) 1465
dna-damage (1454) 1454
proliferation (1420) 1420
survival (1403) 1403
growth (1402) 1402
breast cancer (1400) 1400
cell survival - drug effects (1385) 1385
protein (1378) 1378
rna interference (1370) 1370
pembrolizumab (1363) 1363
cell cycle proteins - genetics (1355) 1355
dna (1352) 1352
hela cells (1323) 1323
ipilimumab (1317) 1317
flow cytometry (1309) 1309
cell line (1300) 1300
review (1294) 1294
medicine (1290) 1290
metastases (1267) 1267
cell growth (1262) 1262
aged (1257) 1257
clinical trials (1250) 1250
inhibitors (1248) 1248
xenograft model antitumor assays (1223) 1223
medicine, research & experimental (1219) 1219
gene expression regulation, neoplastic (1205) 1205
physiological aspects (1205) 1205
pd-1 (1203) 1203
checkpoint kinase 1 (1173) 1173
mice, nude (1161) 1161
protein kinases - metabolism (1160) 1160
antigens (1125) 1125
checkpoint inhibitors (1119) 1119
medical prognosis (1116) 1116
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (26038) 26038
German (124) 124
French (105) 105
Japanese (90) 90
Chinese (86) 86
Russian (20) 20
Spanish (16) 16
Korean (14) 14
Czech (8) 8
Polish (6) 6
Hungarian (3) 3
Dutch (2) 2
Catalan (1) 1
Croatian (1) 1
Italian (1) 1
Norwegian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature reviews. Cancer, ISSN 1474-1768, 2017, Volume 17, Issue 2, pp. 93 - 115
Journal Article
Journal Article
Journal Article
International journal of molecular sciences, ISSN 1422-0067, 2017, Volume 18, Issue 7, p. 1414
...) and histone acetyltransferases (HAT). HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response... 
Histone deacetylase inhibitors | Anti-angiogenic effect | Cell cycle arrest | Drug combinations | Histone deacetylases | Autophagy | Apoptosis | Cancer | HDAC INHIBITORS | autophagy | SUBEROYLANILIDE HYDROXAMIC ACID | HUMAN LEUKEMIA-CELLS | NITRIC-OXIDE SYNTHASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | TUMOR-SUPPRESSOR GENES | apoptosis | VALPROIC ACID | cell cycle arrest | anti-angiogenic effect | CHEMISTRY, MULTIDISCIPLINARY | drug combinations | CELL LUNG-CANCER | EPITHELIAL-MESENCHYMAL TRANSITION | PHASE-II TRIAL | LONG NONCODING RNA | histone deacetylases | cancer | histone deacetylase inhibitors | Immunomodulation - drug effects | Apoptosis - drug effects | Humans | Angiogenesis Inhibitors - pharmacology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Autophagy - drug effects | Acetylation - drug effects | Animals | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Cycle Checkpoints - drug effects | Angiogenesis Inhibitors - therapeutic use | Histone Deacetylase Inhibitors - pharmacology | Antineoplastic Agents - pharmacology | Epigenesis, Genetic - drug effects | Histone Deacetylase Inhibitors - therapeutic use | Gene Expression Regulation, Neoplastic - drug effects | Drug Evaluation, Preclinical
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2016, Volume 44, pp. 51 - 60
.... This article identifies the rates of common and uncommon irAEs associated with each immune checkpoint inhibitor (ICPI... 
Hematology, Oncology and Palliative Medicine | Pembrolizumab | Immune-related adverse events | Renal cancer | Ipilimumab | Nivolumab | Lung cancer | Melanoma | Immune-checkpoint inhibitors | OPEN-LABEL | SINGLE-ARM | ANTI-CTLA-4 ANTIBODY | METASTATIC MELANOMA | ONCOLOGY | ADVANCED MELANOMA | LONG-TERM SAFETY | MALIGNANT MESOTHELIOMA | ENTERIC NEUROPATHY | ADVERSE EVENTS | IPILIMUMAB RETREATMENT | Lung Neoplasms - drug therapy | Skin Neoplasms - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Adrenal Cortex Hormones - therapeutic use | Diarrhea - chemically induced | Infliximab - therapeutic use | Drug Eruptions - drug therapy | Antineoplastic Agents - adverse effects | Colitis - chemically induced | Antilymphocyte Serum - therapeutic use | Colitis - drug therapy | Carcinoma, Renal Cell - drug therapy | Chemical and Drug Induced Liver Injury - etiology | Pituitary Diseases - chemically induced | Pituitary Diseases - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Drug Eruptions - etiology | Neoplasms - drug therapy | Cyclosporine - therapeutic use | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Melanoma - drug therapy | Chemical and Drug Induced Liver Injury - drug therapy | Diarrhea - drug therapy | CTLA-4 Antigen - antagonists & inhibitors | Kidney Neoplasms - drug therapy | Thyroiditis - drug therapy | Thyroiditis - chemically induced | Index Medicus
Journal Article
Cancer cell, ISSN 1535-6108, 2017, Volume 31, Issue 6, pp. 848 - 848.e1
Journal Article